Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.

about

Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.

Item

http://www.wikidata.org/entity/Q54978405

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@en

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@nl

type

Item

label

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@en

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@nl

prefLabel

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@en

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@nl

P1476

Juvenile treatment with mGluR2 ...... adult by acting through GSK3β.

@en

P2093

Bo Xing

http://www.w3.org/2001/XMLSchema#string

Genie Han

http://www.w3.org/2001/XMLSchema#string

Melissa A Snyder

http://www.w3.org/2001/XMLSchema#string

Min-Juan Wang

http://www.w3.org/2001/XMLSchema#string

Wen-Jun Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs

Schizophrenia: a tale of two critical periods for prefrontal cortical development

How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites

Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex

The adolescent brain and age-related behavioral manifestations

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.

P304

359-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROPHARM.2018.05.019

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29793154

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

6050107

http://www.w3.org/2001/XMLSchema#string